Literature DB >> 9166893

Identification of novel heparin-binding domains of vitronectin.

O D Liang1, S Rosenblatt, G S Chhatwal, K T Preissner.   

Abstract

Vitronectin is a multifunctional serum protein which provides a unique regulatory link between cell adhesion, humoral defense mechanism and the hemostatic system, and the heparin-binding properties of vitronectin are thought to have participated in various functional aspects. In addition to the carboxy-terminal glycosaminoglycan-binding motif, we report on two novel heparin-binding domains which were identified using phage display technique. One heparin-binding domain is located between amino acids Asp82 and Cys137 at the end of the connector region, while the other is in the second hemopexin-type repeat, between amino acids Lys175 and Asp219 of the vitronectin molecule. Our findings may shed new light to the activities of vitronectin and its binding to cells, which could not be explained solely on the basis of the known heparin-binding domain.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9166893     DOI: 10.1016/s0014-5793(97)00330-x

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  9 in total

1.  In vitro selection of RNA aptamers directed against protein E: a Haemophilus influenzae adhesin.

Authors:  Anders Barfod; Birendra Singh; Urban Johanson; Kristian Riesbeck; Per Kjellbom
Journal:  Mol Biotechnol       Date:  2014-08       Impact factor: 2.695

2.  The iron-regulated surface determinant B (IsdB) protein from Staphylococcus aureus acts as a receptor for the host protein vitronectin.

Authors:  Giampiero Pietrocola; Angelica Pellegrini; Mariangela J Alfeo; Loredana Marchese; Timothy J Foster; Pietro Speziale
Journal:  J Biol Chem       Date:  2020-06-04       Impact factor: 5.157

Review 3.  Colonization and Infection of Indwelling Medical Devices by Staphylococcus aureus with an Emphasis on Orthopedic Implants.

Authors:  Giampiero Pietrocola; Davide Campoccia; Chiara Motta; Lucio Montanaro; Carla Renata Arciola; Pietro Speziale
Journal:  Int J Mol Sci       Date:  2022-05-25       Impact factor: 6.208

4.  Sialylation of vitronectin regulates stress fiber formation and cell spreading of dermal fibroblasts via a heparin-binding site.

Authors:  Yasunori Miyamoto; Mio Tanabe; Kimie Date; Kanoko Sakuda; Kotone Sano; Haruko Ogawa
Journal:  Glycoconj J       Date:  2016-03-15       Impact factor: 2.916

5.  New insights into heparin binding to vitronectin: studies with monoclonal antibodies.

Authors:  P Anne Underwood; Alan Kirkpatrick; Sue M Mitchell
Journal:  Biochem J       Date:  2002-07-01       Impact factor: 3.857

6.  Inhibition of the Membrane Attack Complex by Dengue Virus NS1 through Interaction with Vitronectin and Terminal Complement Proteins.

Authors:  Jonas Nascimento Conde; Emiliana Mandarano da Silva; Diego Allonso; Diego Rodrigues Coelho; Iamara da Silva Andrade; Luciano Neves de Medeiros; Joice Lima Menezes; Angela Silva Barbosa; Ronaldo Mohana-Borges
Journal:  J Virol       Date:  2016-10-14       Impact factor: 5.103

7.  Identification and therapeutic potential of a vitronectin binding region of meningococcal msf.

Authors:  Darryl J Hill; Natalie J Griffiths; Elena Borodina; Clio A Andreae; Richard B Sessions; Mumtaz Virji
Journal:  PLoS One       Date:  2015-03-31       Impact factor: 3.240

8.  Pseudomonas aeruginosa Uses Dihydrolipoamide Dehydrogenase (Lpd) to Bind to the Human Terminal Pathway Regulators Vitronectin and Clusterin to Inhibit Terminal Pathway Complement Attack.

Authors:  Teresia Hallström; Melanie Uhde; Birendra Singh; Christine Skerka; Kristian Riesbeck; Peter F Zipfel
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

9.  Conserved Patterns of Microbial Immune Escape: Pathogenic Microbes of Diverse Origin Target the Human Terminal Complement Inhibitor Vitronectin via a Single Common Motif.

Authors:  Teresia Hallström; Birendra Singh; Peter Kraiczy; Sven Hammerschmidt; Christine Skerka; Peter F Zipfel; Kristian Riesbeck
Journal:  PLoS One       Date:  2016-01-25       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.